INTRODUCTION AND OBJECTIVES: Data on the oncologic outcomes of high-risk prostate cancer (HRPCa) patients at 20 years after radical prostatectomy (RP) are lacking. The aim of our investigation was to evaluate the long-term patterns of biochemical (BCR), clinical recurrence (CR), cancer specific mortality (CSM) and othercause mortality (OCM) in a multi-institutional database of surgicallytreated HRPCa patients.
INTRODUCTION AND OBJECTIVES:
To estimate the conditional probability of biochemical recurrence (BCR) free survival and cancer-specific mortality (CSM) for men with clinically localized prostate cancer (PCa) treated with radical prostatectomy (RP).
METHODS: The study population consisted of 3576 consecutive patients who underwent laparoscopic radical prostatectomy (LARP) and 2619 men treated with robotic radical prostatectomy (RARP) in the last 15 years at our institution. BCR was defined as PSA0.2 ng/dl. PCa death was defined as patients who died with metastasis in an androgen independent setting. Kaplan Meier and Cox regression methods was used to estimate BCR and CSM conditional probabilities.
RESULTS: Median follow-up was 8.49 years (IQR 4.01-12.97). Positive surgical margins (PSM) were identified in 1202 patients (19.4%); of these, 664 (55.24%) had organ confined disease and 523 (43.51%) had extraprostatic extension (EPE). BCR-free survival rate was significantly higher with RARP (83% vs 77% for laparoscopic surgery at 10 years; p<0.001). Patients with PSA<10 ng/dl BCR-free survival at 10 years was 80% vs 64% for PSA 10-20 ng/dl, and 59% for PSA >20ng/dl; p>0.001. Negative margins, Gleason6 and no extracapsular extension in the specimen were found to have higher BCR-free survival (all p< 0.001). Conditional probability of BCR after surgery 1st year is 6.7%. Those who reach the 2nd year without recurrence have a relapse probability of 4%, (cumulative probability 9.8%) That probability falls to 3.5% after the 3rd year (cumulative probability 13%), 2% after the 4th year (cumulative probability 15%) and is 2.1% after the 5th year (cumulative probability 17%). After 10 years of follow-up without recurrence, the subsequent probability of relapse is 0.8%, (cumulative probability 21%). A total of 92 (1.48%) patients died of disease. Among patients with BCR, those who recur within the first three years of follow-up had higher CSM (9% vs 4% for BCR after 3 years; p¼0.04). The table shows the variables associated with CSM in multivariable analysis.
CONCLUSIONS: We found a 50% decrease in BCR probability in patients who had not recurred with the first 3 years. Similar drop was identified for CSM. This is not only useful for patients counseling but also to optimize postoperative follow-up strategies.
We aimed to assess the risk of cancer-specific mortality (CSM) in patients with PSA persistence after radical prostatectomy (RP) after accounting for other-cause mortality (OCM). We hypothesized that a non-negligible proportion of patients is at risk of dying from other causes and would not benefit from additional cancer therapies.
METHODS: We included 829 patients with localized PCa undergoing RP at two referral centers between 1994 and 2014. All patients had PSA persistence after RP defined as a PSA 0.1 ng/ml at 8 weeks after surgery. A graphical illustration of the 10-year CSM and OCM rates was generated using competing-risks Poisson regression analyses. Patients were stratified according to age (<65 vs. 65 years) and according to their probability of dying from PCa at 10-years (stratified as <10% vs. 10-30% vs. >30%), which was developed from a Cox regression model based on pathologic characteristics and first PSA after surgery. For each strata, survival estimates were calculated. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e987
